MAGI3 and nonpapillary renal cell carcinoma: Therefore, it is proposed that about 20% of ccRCC patients in stage I with MAGI3 exhibited in middle levels (H-score = 4 ~ 6 or mRNA between 200 ~ 261.5 RPKM) may benefit from Sunitinib adjuvant therapy.